Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals Inc. (NASDAQ: IONS), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Cempra (NASDAQ: CEMP) and Immune Design Corp (NASDAQ: IMDZ)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals Inc. (NASDAQ: IONS), ProNAi Therapeutics Inc. (NASDAQ: DNAI), Cempra (NASDAQ: CEMP) and Immune Design Corp (NASDAQ: IMDZ).

Ionis Pharmaceuticals Inc. (NASDAQ: IONS)

In a report released yesterday, Eun Yang from Jefferies reiterated a Sell rating on Ionis Pharmaceuticals Inc (NASDAQ: IONS), with a price target of $12. The company’s shares closed yesterday at $21.36, close to its 52-week low of $21.09.

Yang wrote, “Thrombocytopenia in IONIS-TTRRx & volanesorsen trials should not come as a complete surprise given similar issues & other SAEs including renal toxicity seen with other ASOs therapies (drisapersen, Kynamro). It’s perhaps becoming apparent with longer tx duration & larger pts exposure. We currently don’t assume IONIS-TTRRx in FAC in our model (no estimate change).”

According to TipRanks.com, Yang is a 1-star analyst with an average return of -3.8% and a 57.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Protalix Biotherapeutics, and Alexion Pharmaceuticals.

Ionis Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $39

.
ProNAi Therapeutics Inc. (NASDAQ: DNAI)

Jefferies analyst Brian Abrahams reiterated a Buy rating on ProNAi Therapeutics (NASDAQ: DNAI) yesterday and set a price target of $22. The company’s shares closed yesterday at $6.40.

Abrahams observed, “DNAI announced in-licensing of a preclinical kinase inhibitor, AS-141. We expect DNAI to leverage their drug development expertise to move it into/ through the clinic, and while early, believe the target looks reasonably interesting; the modest upfront should not materially impact the balance sheet and provides some reassurance DNAI’s BD efforts will not necessarily limit resources to expand development of lead drug ‘2258.”

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 11.9% and a 64.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Protalix Biotherapeutics, and Alder Biopharmaceuticals.

ProNAi Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $22

.
Cempra (NASDAQ: CEMP)

Jefferies analyst Eun Yang reiterated a Buy rating on Cempra Inc. (NASDAQ: CEMP) yesterday and set a price target of $42. The company’s shares closed yesterday at $17.89, close to its 52-week low of $14.03.

Yang said, “Positive Ph2 data of oral solithromycin in Japanese pts shows similar non- inferior efficacy vs. fluoroquinolones, observed in Ph3 SOLITAIRE-Oral trial. Partner Toyama to discuss Ph3 protocol with Japanese regulators in 2H16.”

According to TipRanks.com, Yang is a 1-star analyst with an average return of -3.8% and a 57.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Ionis Pharmaceuticals Inc, and Protalix Biotherapeutics.

Currently, the analyst consensus on Cempra Inc. is Moderate Buy and the average price target is $39.50, representing a 120.8% upside

. In a report released yesterday, Cowen & Co. also reiterated a Buy rating on the stock with a $39 price target.
Immune Design Corp (NASDAQ: IMDZ)

In a report released yesterday, Brian Abrahams from Jefferies reiterated a Buy rating on Immune Design (NASDAQ: IMDZ), with a price target of $20. The company’s shares closed yesterday at $12.94.

Abrahams commented, “We had the opportunity to spend time with IMDZ management, and coming out of our meetings we continue to believe their novel IO technologies are underappreciated.”

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 11.9% and a 64.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Protalix Biotherapeutics, and Alder Biopharmaceuticals.

Currently, the analyst consensus on Immune Design is Strong Buy and the average price target is $30, representing a 131.8% upside

. In a report issued on May 11, Wells Fargo also reiterated a Buy rating on the stock.